

FOLEY ■ LARDNER
ATTORNEYS AT LAW

FOLEY & LARDNER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143
202.672.5300 TEL
202.672.5399 FAX
www.foley.com

6697 February 17, 2004 12:01

WRITER'S DIRECT LINE
202.672.5569
smaebius@foley.com EMAIL

CLIENT/MATTER NUMBER
080618-0209

VIA ELECTRONIC MAIL AND U.S. MAIL

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane rm. 1061
Rockville, MD 20852

**CONFIRMATION
COPY**

Re: Docket No. 2003E-0245
Determination of Regulatory Review Period for Purposes of Patent
Extension: REMODULIN

Dear Sir:

These Comments are submitted on behalf of the Applicants (United Therapeutics, Corp.) for Patent Term Extension of Remodulin in response to the January 29, 2004 *Federal Register* Notice requesting comments and petitions of the Patent Term Extension.

The Notice states, on page 4, numbered paragraph 3, that "[i]n its application for patent extension, this applicants seeks 337 days of patent term extension." Contrary to this statement in the Notice, Applicants seek 4 years and 333 days in their application for Patent Term Extension filed July 8, 2002.

Applicants of the Patent Term Extension application for Remodulin request that the FDA publish an errata stating the correct amount of patent term extension that Applicants seek in their application.

Very truly yours,



Stephen B. Maebius

SBM/MCC

BRUSSELS
CHICAGO
DENVER

DETROIT
JACKSONVILLE
LOS ANGELES
MADISON

MILWAUKEE
ORLANDO
SACRAMENTO

SAN DIEGO
SAN DIEGO/DEL MAR
SAN FRANCISCO
TALLAHASSEE

TAMPA
TOKYO
WASHINGTON, D.C.
WEST PALM BEACH

002.1149577.1

2003E-0245

C1